Viking Therapeutics (VKTX) is back in the spotlight with investors eyeing the company’s advancing clinical pipeline, including its VK2735 obesity drug now in phase 3 trials. Expectations are also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback